-
-
-
-
-
-
-
Coya Therapeutics (COYA) Announces Completion of Controlled Phase 2 Study of Low Dose Interleukin-2 (LD IL-2) in Patients with Alzheimer’s Disease
-
-
-
-
-
-
-
Cartesian Therapeutics (RNAC) Receives FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for Descartes-08 for the Treatment of Myasthenia Gravis
-
-
-
-
-
-
-
GRI Bio, Inc (GRI) Presents Positive Preclinical Data from Pipeline of NKT Cell Modulators
-
-
-
-
-
-
-
Lipella Pharmaceuticals (LIPO): Following Guidance from FDA in Type-C Meeting Lipella Pharmaceuticals to Advance Lead Product Candidate to Phase 2b
-
-
-
-
-
-
-
Larimar Therapeutics (LRMR) Announces FDA has Removed Partial Clinical Hold for Nomlabofusp Program
-
-
-
-
-
-
-
Mira Pharma (MIRA) Advances Preclinical Trials Towards an IND Submission This Year for Ketamir-2, a Differentiated Oral Ketamine Analog
-
-
-
-
-
-
-
Esperion (ESPR) and Otsuka Report Bempedoic Acid Met Primary Endpoint in Phase 3 Trial
-
67,135 total articles have been posted to this category.
Sign-up to StreetInsider.com Premium
to see all today's market moving FDA reports.